Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
Neurosci Lett. 2012 Oct 18;528(1):42-5. doi: 10.1016/j.neulet.2012.08.036. Epub 2012 Aug 25.
Hereditary spastic paraplegias (HSP) are heterogeneous neurodegenerative disorders, genetically classified according to the identified disease gene or locus. Clinically, HSP are distinguished in pure and complicated forms. Mutations in the spastin gene (SPAST) are responsible for SPG4 and account approximately for 50% of the dominantly inherited paraplegias with a pure HSP phenotype.
Molecular screening of the SPAST gene allowed the identification of 31 Italian mutation carriers, from 19 unrelated families. Genetic testing was performed by direct sequencing and multiplex ligation-dependent probe amplification. Subjects carrying SPAST mutations were retrospectively evaluated for clinical phenotype and disability score assessment.
We found 12 recurrent mutations, and 7 novel SPAST mutations. Twenty-eight patients exhibited a pure spastic paraplegia phenotype, while 3 subjects were asymptomatic mutation carriers. Four patients were sporadic cases. Age at onset ranged from 10 to 61 years. Disability score increased with age at examination and disease duration. Patients with onset >38 years presented a faster disease progression, and a higher disability functional index, than the patients with earlier onset (p<0.04).
Our study enlarges the number of pathogenic SPAST mutations, and confirms the association with a pure spastic paraplegia phenotype. Age at onset was highly variable and correlates with the rate of disease progression. Future longitudinal clinical studies are needed to confirm these observations.
遗传性痉挛性截瘫(HSP)是一种异质性神经退行性疾病,根据已确定的疾病基因或基因座进行遗传分类。临床上,HSP 分为单纯型和复杂型。SPAST 基因突变导致 SPG4,约占具有单纯 HSP 表型的显性遗传性截瘫的 50%。
对 SPAST 基因进行分子筛查,在 19 个无关家族中鉴定了 31 名意大利突变携带者。通过直接测序和多重连接依赖性探针扩增进行基因检测。对携带 SPAST 突变的受试者进行回顾性临床表型和残疾评分评估。
我们发现 12 个反复出现的突变和 7 个新的 SPAST 突变。28 例患者表现为单纯痉挛性截瘫表型,3 例为无症状突变携带者。4 例为散发性病例。发病年龄从 10 岁到 61 岁不等。残疾评分随检查时的年龄和疾病持续时间而增加。发病年龄>38 岁的患者比发病年龄较早的患者(p<0.04)疾病进展更快,残疾功能指数更高。
本研究扩大了 SPAST 致病性突变的数量,并证实了其与单纯痉挛性截瘫表型的关联。发病年龄高度可变,与疾病进展速度相关。需要进行未来的纵向临床研究来证实这些观察结果。